I
n the United States, an estimated 847 000 persons are living with chronic hepatitis B virus (HBV) infection (1) , and approximately 14 000 deaths that are attributable to it occur each year (2) . About 2 of every 3 persons with chronic HBV infection are unaware of their infection, which contributes to ongoing transmission (3, 4) . Approximately 70% of persons with chronic HBV infection in the United States are foreign-born (2, 5) , and the prevalence among foreign-born persons is 3% to 5% (5) compared with 0.3% in the general population (1) . Most cases in foreign-born persons occur among immigrants from Africa, Asia, and the Pacific Islandsregions with intermediate (2% to 7% prevalence of hepatitis B surface antigen [HBsAg] ) or high (>7% prevalence of HBsAg) endemicity (6) . Other high-burden populations include men who have sex with men (MSM), injection drug users, incarcerated populations, and sexual and household contacts of infected persons (7) .
Between 15% and 40% of persons with chronic HBV infection develop cirrhosis, hepatocellular carcinoma, or liver failure, and 25% die prematurely of these complications (8 -10) . Complications result in increased direct and indirect health care costs (4, 11) totaling approximately $1 billion (12) . Vaccination and screening are cost-effective interventions to reduce the burden of chronic HBV infection, but their use remains low (7, 13) . Only 24.6% of U.S. adults have received a complete hepatitis B vaccine series (13) , and about 60% of HBV- infected persons are unaware of their infection (4) . Screening among at-risk groups can mitigate the burden of chronic HBV infection by promptly identifying infected persons and linking them to care, but its implementation is suboptimal (7) . Approximately 10% to 15% of eligible persons in the United States receive treatment (4) . Linking HBV-infected patients to care facilitates timely treatment for eligible persons (14) and periodic surveillance (every 6 to 12 months) for hepatocellular carcinoma and monitoring of liver aminotransferase and HBV DNA levels, which are important in mitigating morbidity and mortality (8, 15) .
Reducing the burden of chronic HBV infection by increasing vaccination, screening at-risk adults, and providing linkage to care is a public health priority (16, 17) . Although clinical guidelines from the Centers for Disease Control and Prevention (CDC) (7, 18) , the U.S. Preventive Services Task Force (USPSTF) (19) , the American Association for the Study of Liver Diseases (AASLD) (8) , and the Advisory Committee on Immunization Practices (ACIP) (20) have addressed these topics, their recommendations vary and implementation has been suboptimal (4, 7, 13) . Most persons who are at risk for, are susceptible to, or have HBV infection are not screened, vaccinated, or linked to care (4, 7, 13) . Recent studies have suggested additional at-risk groups that should receive HBV screening, treatment, or vaccination that were not in previously published clinical guidelines (21) (22) (23) (24) (25) (26) (27) . This article by the American College of Physicians (ACP) and the CDC presents the best available evidence on hepatitis B vaccination, screening, and linkage to care. Using the ACP highvalue care framework, we highlight consensus across guidelines and integrate this with current evidence for hepatitis B vaccination, screening, and linkage to care from the research literature to develop best practice advice statements. This evidence-based synthesis of current clinical guidelines and research findings is intended to amplify existing guidelines and promote high-value clinical practice. The target audience for this article includes all clinicians, and the target patient population is adults who are at risk for or have HBV infection.
METHODS

Literature Review
A narrative literature review of evidence on hepatitis B vaccination, screening, and linkage to care was conducted. We searched the published Englishlanguage literature from January 2005 (when highly potent hepatitis B drug treatment with low resistance rates became available) We selected current clinical guideline recommendations from the CDC, the USPSTF, the AASLD, and the ACIP and included systematic reviews, meta-analyses, and randomized and nonrandomized intervention studies from the research literature. Selected articles were further screened to include those that focused on the most recent guidelines on vaccination, screening, and treatment for chronic HBV infection; barriers to screening and linkage to care; adverse events associated with vaccination; and strategies to increase screening, vaccination, and linkage to an HBVexperienced provider among adults. Selected articles were reviewed by 2 persons to ensure that they met the selection criteria.
Consensus Process and Approval
This article was reviewed and approved by the CDC and the ACP High Value Care Task Force, whose members are physicians trained in internal medicine and its subspecialties and include experts in evidence synthesis who are familiar with the hepatitis literature. The CDC and the task force developed the best practice statements (summarized in the Figure) on the basis of the narrative review and approved them by consensus. All disclosures of interest were declared at each conference call. No individuals were recused from discussion or voting due to conflicts of interest.
VACCINATION
Vaccination is the most effective measure to prevent HBV infection and its complications (18) . The vaccine confers protection in more than 90% of healthy adults younger than 40 years who receive the complete vaccine series (28, 29) , and immunity lasts at least 3 decades (30 -32) . Recommendations for hepatitis B vaccination were introduced in 1982 and have since evolved into a comprehensive immunization strategy, although challenges remain (18) . The ACIP recommends vaccination for all unvaccinated adults at risk for HBV infection, including sexual partners and household contacts of HBsAg-positive persons; sexually active persons who are not in a mutually monogamous relationship; persons seeking evaluation for a sexually transmitted infection; MSM; recent or current users of injection drugs; residents and staff at facilities for developmentally challenged persons; incarcerated persons; health care workers and public safety employees at risk for exposure to blood or blood-contaminated body fluids; adults aged 19 to 59 years with diabetes mellitus; persons with end-stage renal disease, including those receiving predialysis care, hemodialysis, peritoneal dialysis, or home dialysis; persons with chronic liver disease, including but not limited to hepatitis C virus infection, cirrhosis, nonalcoholic fatty liver disease, alcoholic liver disease, autoimmune liver disease, or an alanine aminotransferase (ALT) or aspartate aminotransferase level greater than twice the upper limit of normal; pregnant CLINICAL GUIDELINE Hepatitis B Vaccination, Screening, and Linkage to Care women who are at risk during pregnancy (>1 sex partner during the previous 6 months, previous evaluation or treatment for a sexually transmitted infection, recent or current injection drug use, or HBsAg-positive sex partner); HIV-infected persons; international travelers to regions with high or intermediate levels of endemic HBV infection; and any adult seeking protection from HBV infection (18, 20, 33) . Adults in the following settings are also assumed to be at risk: sexually transmitted disease treatment facilities, HIV testing and treatment facilities, facilities providing drug abuse treatment and preventive services, health care settings targeting injection drug users and MSM, correctional facilities, hemodialysis facilities and end-stage renal disease programs, and institutions and nonresidential day care facilities for developmentally disabled persons (18) .
Hepatitis B vaccine is usually given as a 3-or 4-dose series, but higher dosages may be required for immunocompromised persons and those with endstage renal disease (18, 34, 35) . These persons should receive postvaccination testing, and those with suboptimal response (antibody to HBsAg level <10 mIU/mL) should be revaccinated (18, 34, 35) .
Since the implementation of universal hepatitis B vaccination among infants and the ACIP's recommendations, there has been a significant decrease in the rate of acute HBV infection in adults (9.6 per 100 000 persons in 1982 vs. 1.1 per 100 000 persons in 2015) (18, 36 ) and the proportion of noninstitutionalized persons who have ever been infected with HBV (5.5% during 1988 to 1994 vs. 3.7% during 2007 to 2012) (1) . Because of the low vaccination coverage and the risk for HBV transmission (13), increasing coverage among unvaccinated adults is essential.
Best Practice Advice 1
Clinicians should vaccinate against chronic hepatitis B virus (HBV) 
SCREENING
Current guidelines from the CDC (7), the USPSTF (19) , and the AASLD (8) recommend screening for specific populations and persons at increased risk for chronic HBV infection. Table 1 summarizes these populations and at-risk groups, the prevalence of HBV infection among them, and screening recommendations. Although recommendations for some groups vary, all 3 organizations recommend screening for persons born in regions with intermediate-to-high prevalence of HBV infection ( Table 2) or with other known HBV-related risks. In addition, prevaccination testing is recommended for health care personnel at increased risk for HBV infection and those who perform exposure-prone procedures (47). Despite these recommendations, screening in these groups is suboptimal (4, 11, 48, 49) . Table 3 shows HBV screening seromarkers (HBsAg, antibody to HBsAg, and antibody to hepatitis B core antigen), associated clinical states, and recommended clinical management. Screening for HBV with HBsAg testing is only recommended for pregnant women.
Persons receiving chemotherapy or immunosuppressive therapy should be screened for HBV because of the risk for virus reactivation (21, 22, 26) . Cases of HBV reactivation have also been reported among patients receiving direct-acting antivirals for hepatitis C virus infection (23) (24) (25) . Reactivation can result in hepatocellular injury, fulminant hepatitis, liver failure, and death (21) (22) (23) (24) (25) (26) . Clinicians should therefore screen all patients receiving chemotherapy, immunosuppressive therapy, or direct-acting antivirals.
Best Practice Advice 2
Clinicians 
LINKAGE TO CARE
Linkage to care is the process of referring patients with chronic HBV infection to medical care and ensuring that they receive directed care and treatment. Although not all patients with chronic HBV infection require treatment, they all should be routinely evaluated for hepatocellular carcinoma and treatment eligibility through history and physical examination (50, 51) . Patients who are linked to care can achieve significant reductions in HBV-associated morbidity and mortality (4, 11, 52, 53) . However, most persons with chronic HBV infection are not linked to care because they are unaware of their infection (4) or are not referred despite their diagnosis (54) . Between 20% and 40% of persons with chronic HBV infection require treatment; however, all require monitoring of liver aminotransferase and HBV DNA levels (4, 8) . Only 10% to 15% of eligible persons receive antiviral therapy, demonstrating that many who could benefit from therapy do not receive it (4). Linkage to care ensures that patients with chronic HBV infection receive treatment when they become eligible (elevated HBV DNA and liver aminotransferase levels), hepatocellular carcinoma surveillance, behavioral risk reduction counseling, and vaccination of susceptible sexual and household contacts (8, 18, 55) .
Best Practice Advice 3
Clinicians should provide or refer all patients identified with HBV (HBsAg-positive) for posttest counseling and hepatitis B-directed care.
HARMS OF VACCINATION, SCREENING, AND LINKAGE TO CARE
Adverse effects from hepatitis B vaccination are rare and mild; the most common are soreness at the injection site (3% to 29%) and mild fever (1% to 6%) (18) . Anaphylaxis after vaccine administration has been reported (56) but is rare, occurring once per 1.1 million doses (57) . The vaccine is contraindicated in persons 
COSTS OF VACCINATION, SCREENING, AND LINKAGE TO CARE
Hepatitis B vaccination, screening, and linkage to care are cost-effective (59 -65) . A study examined the cost-effectiveness of routine vaccination compared with no vaccination at a sexually transmitted infection clinic and showed that the incremental cost-effectiveness ratio (ICER) associated with routine vaccination was $3500 per quality-adjusted life-year (QALY) gained (66) . Another analysis showed that screening of immigrants from HBV-endemic countries was cost-effective (<$50 000 per QALY gained) (63) .
A study comparing the cost-effectiveness of 2 HBV screening strategies (screening and treatment, or screening and treatment of the index case patient and vaccination of their close contacts) versus voluntary screening among Asian or Pacific Island-born persons in the United States found ICERs of $36 088 per QALY gained for the first strategy and $39 903 per QALY gained for the second strategy (59) . Similarly, a costeffectiveness analysis of screening and treatment programs among Asian-born persons in the United States found that screening and treatment were cost-effective ($46 489 per QALY gained) compared with no screening (62) . Another study compared the cost-effectiveness of early-versus late-stage treatment over a 20-year period. The study found an ICER of $19 505 per QALY gained at 10 years that progressively decreased to $5184 per QALY gained at 20 years among persons in the early-stage treatment group (61) . More recent models have demonstrated the cost-effectiveness of screening and treatment or vaccination among groups with ICERs less than $18 009 (Centers for Disease Control and Prevention. Unpublished data).
Hepatitis B vaccination and screening are also costsaving (7, 67) . The price per vaccine dose ($24 to $62) is substantially lower than the medical costs associated with treatment of chronic HBV infection ($4000 to $26 000), decompensated cirrhosis ($38 932 to $153 110), and liver transplantation ($343 241 to $514 862) in the first year (60, 66 -68) . Furthermore, the cost of screening in populations with an HBsAg prevalence of at least 2% is $750 to $3752 per case of chronic HBV infection identified (7), significantly lower than the annual medical costs.
DISCUSSION What Is the Current State of Practice in the United States?
There are gaps in vaccination and screening of persons at risk for HBV infection. Current estimates show that vaccination coverage (≥3 doses) is 24.6% among adults aged 19 years or older (13) and is lower for black persons (29.4%) and Hispanic persons (22.5%) than white persons (34.9%) (13) . Vaccination coverage among high-risk adults (MSM, injection drug users, and persons at risk for HIV and other sexually transmitted infections) is approximately 45% (69). In addition, coverage is approximately 20.7% among foreign-born adults in the United States compared with 25.5% among U.S.-born adults, 25.3% among adults with health insurance compared with 19.4% among those without, 27.4% among adults with chronic liver conditions, and 64.7% among health care personnel (13) .
Prevalence of HBV screening is 11% to 67% among foreign-born persons (48, 70) , 28% to 52% among MSM (49, 71) , and approximately 28% among patients receiving chemotherapy (72) . The prevalence of guideline-adherent treatment and care among persons with chronic HBV infection is low (4, 73, 74) . Between 10% and 15% of eligible persons in the United States receive treatment (4), 40% to 78% of patients with chronic HBV infection receive recommended ALT monitoring (54, 73, 75) , and fewer than 40% are monitored for HBV DNA (54, 73) . Periodic assessment of ALT and HBV DNA levels is important to evaluate disease progression and treatment eligibility.
Why Does Practice Not Follow the Evidence?
Many barriers contribute to low rates of hepatitis B vaccination, screening, and linkage to care, especially in foreign-born populations (76 -80). Patient-level barriers include lack of knowledge about chronic HBV in- anti-HBc = antibody to hepatitis B core antigen; anti-HBs = antibody to hepatitis B surface antigen; HBsAg = hepatitis B surface antigen; HBV = hepatitis B virus. * Can be the result of a false-positive result, which requires repeated testing; past infection or passive transfer to an infant born to an HBsAg-positive mother, which requires no action; or occult HBV infection, which needs to be known if the patient ever becomes immunosuppressed, receives chemotherapy, or is treated with antiviral therapy for hepatitis C virus infection and warrants consideration of monitoring of HBV DNA levels.
Hepatitis B Vaccination, Screening, and Linkage to Care CLINICAL GUIDELINE fection, ignorance about the hepatitis B vaccine and its health benefits, misinformation about vaccines, low levels of English language proficiency, cultural and language differences, lack of health insurance or access to health care resources, and difficulty navigating the health care system (76, 77) . In some communities, stigma associated with chronic HBV infection and fear of a positive test result can present challenges to screening and care (80, 81) . Clinician-level barriers include a lack of awareness about clinical care guidelines and the risk for chronic HBV infection in certain populations (76, 82, 83) , resulting in missed opportunities for vaccination or screening (79) . Failure to screen for HBV infection or monitor liver aminotransferase and HBV DNA levels and lack of awareness of current treatment guidelines among physicians are some reasons that many treatment-eligible patients are missed (4, 79) . The hepatitis B vaccine may also not be routinely stored in some clinical practices, and this can present challenges to vaccination in the clinical setting (84) .
System-level barriers include limited hepatitis B funding for programs for uninsured adults (74) and the complexities surrounding payments for adult vaccines by insurers (85) . The complex health care system, which may require referral to a liver specialist or an HBVexperienced health care provider, may present a barrier to persons who lack knowledge about the way the health care system works (77).
Evidence-Based Strategies to Increase Hepatitis B Vaccination, Screening, and Linkage to Care
Various strategies have been implemented in clinical and community settings to increase hepatitis B vaccination, screening, and linkage to care (86 -92) . Partnerships between community-based programs and local health centers with culturally and linguistically competent patient navigators have proved effective in increasing patient awareness of chronic HBV infection, identifying infected adults, vaccinating susceptible persons, linking infected persons to care and complementary resources, and overcoming cultural and linguistic barriers to high-quality care (87) (88) (89) (90) 92) . The provisions of the Patient Protection and Affordable Care Act can increase vaccination coverage because they enable uninsured susceptible adults to receive the vaccine without cost sharing (93) .
Clinicians should routinely assess HBV risk and vaccine needs, discuss health benefits of vaccination and screening during clinical encounters, and offer vaccination and screening when indicated (84) . When a patient is infected with HBV, household and sexual contacts should be screened, susceptible contacts should be vaccinated, and infected contacts should be linked to care. Increasing clinicians' awareness of the importance of HBV screening, monitoring liver aminotransferase and HBV DNA levels, and adherence to treatment guidelines can increase the number of eligible patients receiving treatment (4, 79) . Clinical practices that do not stock the hepatitis B vaccine can coordinate with local health departments or large practices that stock the vaccine to refer susceptible patients and ensure they are vaccinated (94).
The Community Preventive Services Task Force has recommended clinician-based or health care systembased interventions, including electronic medical record (EMR) prompts, provider education, vaccine recommendation by a provider, standing orders or protocols for HBV screening and vaccination, and patient reminders and recall systems when vaccines are due (91). In the Indian Health Service, EMR prompts (86) . Including hepatitis B vaccination as part of routine preventive services to all unvaccinated adults in settings with a high proportion of adults with risk factors for HBV infection (sexually transmitted infection clinics, health care facilities that serve injection drug users and MSM, and correctional health care facilities) is another useful strategy (66) . Software algorithms have been successfully used to identify names associated with foreign birth so that EMR reminders can prompt the provider to assess HBV screening and vaccination status (96, 97) . This system can complement existing strategies to identify patients at risk for chronic HBV infection. Culturally competent peer navigators can also mitigate system-level barriers that a complex health care system may present to patients with chronic HBV infection (98, 99) . Table 4 summarizes barriers at the patient, clinician, and system level and strategies to overcome them.
The current low hepatitis B vaccination coverage among adults necessitates reconsideration of the existing risk-based vaccination strategy. Because the administration schedule typically includes 3 vaccine doses over 6 months, the vaccine series needs to be started and completed before exposure to the risk factor to protect persons at greatest risk. Furthermore, the multitude of factors constituting an indication for adult hepatitis B vaccination can create implementation challenges for vaccine providers. An adult vaccination strategy that is not based on risk may be the next step toward achieving elimination.
The burden and costs associated with chronic HBV infection in the United States are high. Vaccination of susceptible adults is important to prevent infection and reduce ongoing transmission. Screening in high-risk populations is the first step in the care cascade to identify persons with chronic HBV infection, and vaccination and linkage to care are effective at reducing HBVassociated morbidity and mortality. The best practice advice statements in this article amplify and complement existing clinical guidelines by reiterating the importance of hepatitis B vaccination and screening in atrisk persons and linking infected persons to care. Evidence-based strategies that effectively implement this advice are critical to accomplishing the goals of the national hepatitis B elimination plan. Current author addresses and author contributions are available at Annals.org.
